2 Sector ETFs to Keep an Eye on in 2023

NYSE: XLV | SPDR Select Sector Fund - Health Care News, Ratings, and Charts

XLV – Growing concerns over the possibility of a recession due to high inflation and the Fed’s interest rate hikes are expected to keep the stock market under pressure in the near term. Therefore, investors could hedge their portfolios against the economic downturn by adding quality ETFs Health Care Select Sector SPDR Fund (XLV) and Energy Select Sector SPDR Fund (XLE) to their watchlist. Read more….

The stock market was on a wild ride last year due to the double whammy of skyrocketing inflation and the Fed’s interest rate hikes, coupled with geopolitical tensions. However, a series of recent positive economic data boosted investors’ confidence.

Inflation fell for the sixth consecutive month to 6.5% in December, bolstering hopes of a soft landing among investors and smaller interest rate hikes by the Federal Reserve going forward. Despite the steady waning, the central bank remains committed to bringing inflation down to its 2% target, implying more interest rate hikes this year.

Many economists believe the Fed’s aggressive regime has triggered a broader slowdown in the economy, predicting a 61% chance of a recession in 2023. This is expected to keep the stock market under pressure this year.

Irrespective of the market conditions, Exchange-Traded Funds (ETFs) can be useful for investors who are unsure of which individual stocks to buy, as they cover a basket of securities, thereby mitigating risk while enjoying broad upside opportunities at a low price.

Two ETFs that investors should keep an eye on in 2023 are the Health Care Select Sector SPDR Fund (XLV) and Energy Select Sector SPDR Fund (XLE). These ETFs’ diverse holdings could help investors generate substantial returns.

Health Care Select Sector SPDR Fund (XLV)

XLV invests in stocks of companies operating across healthcare sectors in the United States and growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of publicly traded equity securities of companies in the Health Care Select Sector Index by using the full replication technique.

As of January 23, XLV has $41.46 billion in assets under management (AUM) management and a Net Asset Value (NAV) of $134.38. Its expense ratio of 0.10% is lower than the category average of 0.53%.

The fund’s top holdings include UnitedHealth Group Inc (UNH) with a 9.05% weight, Johnson & Johnson (JNJ) with an 8.86% weight, and Merck & Co., Inc. (MRK) with a 5.57% weight. It has a total of 65 holdings.

XLV’s annual dividend of $1.99 yields 1.48% on prevailing prices. Its dividend payouts have increased at an 8.9% CAGR over the past three years and a 10.4% CAGR over the past five years. The ETF has a four-year average yield of 1.67%.

The fund’s net inflows came in at $6.51 billion over the past year. XLV has gained 6.2% over the past three months and 3.8% over the past year to close the last trading session at $134.37. It has a five-year beta of 0.69.

XLV’s solid prospects are reflected in its POWR Ratings. The ETF has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

The ETF has an A grade for Trade and Buy & Hold. Among the 42 ETFs in the B-rated Health & Biotech ETFs group, XLV is ranked first. To see XLV’s rating for Peer, click here.

Energy Select Sector SPDR Fund (XLE)

XLE aims to provide before-expenses investment results that correspond with the price and yield performance of the Energy Select Sector Index companies. The fund follows a replication strategy and offers exposure to the U.S. energy sector.

As of January 23, XLE has a $42.52 billion AUM and a NAV of $90.55. Its expense ratio of 0.10% compares to the category average of 0.46%. The fund’s top holdings include Exxon Mobil Corporation (XOM) with a 22.56% weight, Chevron Corporation (CVX) with a 19.51% weight, Schlumberger Limited (SLB) with a 5.02% weight, and ConocoPhillips (COP) with a 4.46% weight.

XLE’s annual dividend of $3.22 yields 3.56% on prevailing prices. Its dividend payouts have increased at a 12.8% CAGR over the past three years and an 8% CAGR over the past five years. The fund has a four-year average yield of 5.54%.

Over the past month, the fund’s net inflow came in at $881.45 million. XLE has gained 45.1% over the past year to close its last trading session at $90.60. It has a five-year beta of 1.50.

XLE’s strong fundamentals are reflected in its POWR Ratings. The ETF has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.

It has a Trade, Buy & Hold, and Peer grade of A. In the 46-fund B-rated Energy Equities ETFs group, it is ranked #1. Click here to see all POWR Ratings for XLE.


XLV shares were trading at $133.23 per share on Tuesday afternoon, down $1.14 (-0.85%). Year-to-date, XLV has declined -1.93%, versus a 4.73% rise in the benchmark S&P 500 index during the same period.


About the Author: Shweta Kumari


Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
XLVGet RatingGet RatingGet Rating
XLEGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


How Low Could Stocks Go?

The S&P 500 (SPY) is starting to test key support levels for the first time since November 2023 given continuing signs that Fed rate cuts are getting pushed further and further into the future. This begs the question of “how low could stocks go?” 44 year investment veteran Steve Reitmeister does his level best to answer that question including a trading plan and top picks to stay one step ahead of the market. Read on below for the full story...

3 Biotech Stocks to Buy to Power Through April

The biotech sector is primed for growth, fueled by a surge in FDA approvals, anticipated M&A deals, and the integration of AI in drug discovery. So, fundamentally sound biotech stocks Theratechnologies (THTX), Harmony Biosciences (HRMY), and Shionogi & Co. (SGIOY) might be solid buys in this month. Keep reading...

Check out These 3 Internet Stocks for Potential Gains

Amplified internet usage, technological advancements, and a rising digital transformation worldwide have driven the internet industry rapidly. To that end, quality internet stocks Wix.com (WIX), Tripadvisor (TRIP), and Yelp (YELP) could be solid buys now. Read on…

Top 3 Financial Services Stocks With Unstoppable Momentum

The financial services sector is set for solid growth owing to global economic trends, technological advancements making digital services more accessible, and changing consumer preferences.Therefore, investors could consider buying fundamentally strong financial services stocks Broadridge Financial Solutions (BR), Banco Macro (BMA), and Yiren Digital (YRD) as they look well-positioned to continue their momentum. Read more...

Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Read More Stories

More SPDR Select Sector Fund - Health Care (XLV) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All XLV News